Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18812865 | 0.85 | LMNA (0.65) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL12325527 | 0.85 | KMT2A (0.63) | MEN1KMT2AMAPTLMNAMGLL | |
| SCHEMBL29463677 | 0.85 | LMNA (0.65) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL17761731 | 0.85 | MGLL (0.54) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL6183972 | 0.85 | ALDH1A1 (0.52) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL6183422 | 0.83 | ALDH1A1 (0.53) | MEN1KMT2AMAPTLMNAMGLL | |
| SCHEMBL6180150 | 0.83 | ENPP2 (0.57) | MEN1KMT2AMAPTLMNACYP1A2 | |
| SCHEMBL7383453 | 0.83 | MAPT (0.72) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL17653813 | 0.83 | MGLL (0.54) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL6179243 | 0.82 | ALDH1A1 (0.52) | MEN1KMT2AMAPTLMNAMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893066-B2 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | GILEAD PALO ALTO, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893066-B2 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | GILEAD PALO ALTO, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893066-B2 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | GILEAD PALO ALTO, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2276748-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009126123-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126123-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20080255130-A1 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | GILEAD PALO ALTO, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255130-A1 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | GILEAD PALO ALTO, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255130-A1 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | GILEAD PALO ALTO, INC. | 2008-10-16 | — | — | US | disclosed |
| EP-1320522-B1 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-6660742-B2 | Alkylation therapy; anticancer agent | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2003-12-09 | — | — | US | disclosed |
| US-20030073731-A1 | Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins | MEDIMMUNE LIMITED (GB) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255130-A1 | N-[2-(6-{[(3,4-dichlorophenyl)methyl]amino}-2-(4-methoxyphenyl)-3-oxo-4-hydropyridino[2,3-b]pyrazin-4-yl)ethyl]acetamide derivatives; antidiabetic agents; abnormal lipid levels, obesity; cardiovascular, skin and metabolic disorders | SCD, SCD5, FASN | MEN1 4849/4885KMT2A 902/4885MAPT 4376/4885 |
| US-20030073731-A1 | Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins | DDB1, ERCC2, SSU72 | MEN1 1970/4885KMT2A 3055/4885MAPT 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.